OBAT now publicly listed, offering warrant bonus and dividend
13 Jan 2025 09:49
It is worth noting that OBAT has consistently distributed dividends to its shareholders, amounting to IDR 40 billion over the past five years.
First half of 2024 saw PYFA’s loss worsening 155.79%
05 Aug 2024 10:31
The net loss of PT Pyridam Farma Tbk (PYFA) worsened 155.79% year-on-year (yoy) in the first half of 2024 compared to the same period in 2023 although sales growth reached 29.87% yoy.
Expanding to Australia, PYFA wraps up Probiotec acquisition
20 Jun 2024 09:48
PT Pyridam Farma Tbk’s (PYFA) steps in expanding the market to Australia is now materialised after acquiring the entire shares of Probiotic Limited, Australia.
Eyeing 7% growth, DVLA prepares capex of IDR 209 billion
11 Jun 2024 17:31
PT Darya-Varia Laboratoria Tbk (DVLA) is reportedly preparing capital expenditure (capex) budget worth IDR 209 billion for 2024, which will mostly be allocated for expansion.
Distributing another IDR 65, Darya-Varia’s dividend clocks up to IDR 108 per share
11 Jun 2024 16:00
PT Darya-Varia Laboratoria Tbk (DVLA) sets up IDR 65 per share for the final dividend of the fiscal year (FY) 2023, totalling IDR 72.8 billion, which will be taken out of its current year’s net profit in 2023.
Seeing 130.96% downturn, PYFA lost IDR 85.22 billion
15 Mar 2024 09:55
The performance of PT Pyridam Farma Tbk (PYFA) declined throughout 2023 compared to 2022.
Brand-name drugs sales rose 14.9%, Phapros’s profit still declined
27 Jul 2023 15:58
Although its profit went down by almost 30% in the first half of 2023, PT Phapros Tbk (PEHA) managed to record an increase in brand-name drugs sales.
Q1 2023 performance slows down, PEHA to give out dividend
08 Jun 2023 17:33
PT Phapros Tbk (PEHA), a pharmaceutical product manufacturer, readies dividend of IDR 11.2 billion that will be taken out of its net profit in 2022.
Phapros prepares ethical drug to become growth pillar for 2023
02 May 2023 18:03
PT Phapros Tbk (PEHA) posted growth in sales of ethical drugs, namely branded prescription drugs, up to 8.9% year-on-year (yoy) at the end of the first quarter of 2023
SIDO secured IDR 300.27 billion of profit in Q1
28 Apr 2023 11:11
PT Industri Jamu dan Farmasi Sido Muncul Tbk (SIDO) collected IDR 907.30 billion of revenue and IDR 300.237 billion of profit in Q1 2023.
